Lyfe Capital
Sequoia leads Series A extension for China's ProfoundBio
Sequoia Capital China has led a USD 70m extended Series A round for ProfoundBio, a Chinese drug developer with two cancer treatments entering phase-one clinical trials.
China digital CRO Elixir raises $52m
Elixir, a China-based clinical research organisation (CRO), has raised a USD 52m Series A round from Lyfe Capital, Chow Tai Fook Investment, and Sinovation Ventures.
Deal focus: Medilink chases global ADC opportunity
The Medilink Therapeutics team spun out from Kelun-Biotech to develop antibody drug conjugates capable of competing with the world’s best. Its USD 70m Series B will support the pursuit of this goal
Lyfe, Qiming lead Series B for China ADC player Medilink
Suzhou Medilink Therapeutics, a Chinese biotech company specializing in antibody-drug conjugates (ADCs) commonly used as targeted therapies for treating cancer, has raised a USD 70m Series B led by Lyfe Capital and Qiming Venture Partners.
Goldman, Sofina lead Series C for China CDMO Zhenge
Goldman Sachs Asset Management and Sofina have led a USD 100m Series C round for Zhenge Biotech, a Shanghai-based contract development and manufacturing organisation (CDMO).
Biotech player CANbridge drops on debut after $87m HK IPO
CANbridge Pharmaceuticals, a Beijing-based drug developer that focuses on treatments for cancer and rare diseases, lost 27% in value on its Hong Kong trading debut following a HK$685.1 million ($87.8 million) IPO.
Hong Kong sees rush of VC-backed biotech IPO filings
Five VC-backed pre-revenue Chinese biotech companies have filed to list in Hong Kong over the past two weeks, doubling the size of the IPO pipeline in this category.
China drug development outsourcer raises $70m
Zhenge Biotech – a Shanghai-based contract development and manufacturing organization (CDMO) for large molecule drugs – has raised $70 million in Series B funding led by Qiming Venture Partners and IDG Capital.
Chinese medical robot maker raises $93m
Edge Medical, a China-based manufacturer of surgical robots, has raised a RMB600m ($93m) series B round led by Lyfe Capital and Hong Kong-listed Kangji Medical.
3W leads $43m Series E for China's CANbridge
Hong Kong’s 3W Fund Management has led a $43 million Series E round for CANbridge Pharmaceuticals, a Beijing-based drug developer that focuses cancer and rare diseases.
Cell analysis player Cytek raises $120m Series D
RA Capital and Hillhouse Capital have led a $120 million Series D round for Cytek Biosciences, a California-based cell analysis start-up founded by a former professor at Shanghai's Fudan University.
China's Burning Rock soars on debut after $222m US IPO
Burning Rock Biotech, a venture capital-backed, China-based provider of genetic testing services used in cancer diagnosis, rose 49% on its trading debut following a $222.8 million US IPO.
China’s Burning Rock Biotech files for US IPO
Burning Rock Biotech, a venture capital-backed, China-based provider of genetic testing services used in cancer diagnosis, has filed for an IPO in the US.
Shanghai CDMO player gets $51m Series A
Zhenge Biotech – a Shanghai-based contract development and manufacturing organization (CDMO) for large molecule drugs – has raised $51 million in Series A funding led by Lyfe Capital.
Chinese investors lead round for US influenza specialist
Ansun BioPharma, a US-based drug developer led by a former executive at healthcare-focused VC firms Caduceus Asia Partners and OrbiMed, has raised $80 million in Series B funding from a predominantly Chinese investor base.
HiFiBiO Therapeutics receives $67m in Series C funding
HiFiBiO Therapeutics, a drug developer led by the former head of Asian cancer research at Sanofi, has completed a $67 million Series C funding round.
GIC leads $125m round for China cancer diagnostics business
GIC Private has led a RMB850 million ($125.5 million) Series C round for Burning Rock, a Chinese cancer diagnostics start-up that is already working with hospitals on products based on DNA sequencing analysis.
Traditional Chinese medicine: Innovating antiquity
As the time-honored but largely unprofessional industry of traditional Chinese medicine reinvents itself for the 21st century, private equity could play a role in a massive healthcare overhaul
Ping An healthcare app files for Hong Kong IPO
Ping An Healthcare & Technology - the PE-backed business that runs the healthcare-focused mobile app known as Ping An Good Doctor in China - is seeking a separate listing in Hong Kong from its parent company Ping An Insurance.
The crystal ball: Predictions for 2018
From China to Australia and secondaries to venture debt, industry participants share their perspectives on the year to come for fundraising, investments and exits
GP-LP: Dangerous liaisons
A diverging supply-demand dynamic in private equity fundraising is threatening the GP-LP alignment of interest. Concessions on both sides are needed in the interests of long-term stability
Fund focus: Lyfe attracts a diversified following for Fund II
Having been supported by fund-of-funds when raising its first China healthcare vehicle, Lyfe Capital has added pension funds, endowments and family offices to its $420 million second fund
China’s Lyfe Capital raises $420m for second healthcare fund
China-based healthcare specialist Lyfe Capital has raised more than $420 million for its second fund, which comprises parallel US dollar and renminbi-denominated tranches.